Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfisomidine SCHEMBL34791 | 0.83 | PDE4A (1.00) | PDE4AAGO2ALDH1A1LMNAKDM4E | |
| Sulfisomidine SCHEMBL284793 | 0.82 | PDE4A (0.97) | PDE4AAGO2ALDH1A1LMNAKDM4E | |
| SCHEMBL5450137 | 0.82 | ALDH1A1 (0.68) | ALDH1A1LMNAKDM4EPOLBTDP1 | |
| SCHEMBL1828300 | 0.80 | PDE4A (0.74) | PDE4AAGO2ALDH1A1LMNAKDM4E | |
| SCHEMBL1381858 | 0.80 | PDE4A (0.73) | PDE4AAGO2ALDH1A1LMNAKDM4E | |
| Sulfamethazine SCHEMBL28086389 | 0.77 | PDE4A (0.87) | PDE4AAGO2ALDH1A1LMNAKDM4E | |
| SCHEMBL11757838 | 0.77 | PDE4A (0.69) | PDE4AAGO2ALDH1A1LMNAKDM4E | |
| SCHEMBL21637832 | 0.77 | USP2 (0.71) | ALDH1A1LMNAKDM4EPOLBUSP2 | |
| SCHEMBL12464128 | 0.77 | POLB (0.66) | PDE4AAGO2ALDH1A1LMNAKDM4E | |
| SCHEMBL2854889 | 0.77 | ALDH1A1 (0.70) | ALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | PDE4A 137/4885AGO2 3286/4885ALDH1A1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.